99%+ Purity
COA Included
Sealed Vials
Survodutide
GCGR/GLP dual agonist for metabolic control
GCGR/GLP dual agonist
Key Benefits
- Dual receptor targeting for comprehensive support
- May enhance glucose-dependent insulin response
- Research suggests improved satiety signaling
- Supports healthy energy expenditure pathways
- Once-weekly dosing for convenient administration
- Advanced peptide engineering for stability
- May help prevent hypoglycemic episodes
Melt Fat While Protecting Your Metabolic Engine
Most weight loss approaches trash your metabolism, leaving you hungry, tired, and fighting rebound weight gain. This dual-pathway approach actually prevents metabolic slowdown while accelerating fat loss. You get the aggressive results without the hormonal crash that sabotages everything.
Dual GCGR/GLP-1R activation for balanced metabolic regulation
About Survodutide
Survodutide is an engineered dual agonist peptide that simultaneously activates glucagon and GLP-1 receptors, creating a unique metabolic profile. This combination delivers enhanced fat mobilization and appetite control while preventing the metabolic suppression that typically accompanies significant weight loss. The once-weekly dosing protocol maintains consistent metabolic support throughout your transformation.
Who It's For
Designed for individuals who need serious fat loss results without compromising long-term metabolic health. This represents a fundamental shift from traditional approaches that force you to choose between rapid results and sustainable metabolism. Ideal for advanced protocols where maintaining muscle mass and energy levels during aggressive cutting phases is critical.
Research Background
Survodutide represents an innovative approach to metabolic therapy by targeting two complementary hormone pathways simultaneously. The dual agonist mechanism combines the well-established benefits of GLP-1 receptor activation—including enhanced insulin secretion, reduced appetite, and delayed gastric emptying—with glucagon receptor activation that promotes energy expenditure and may help prevent hypoglycemia. This unique combination aims to address the complex metabolic dysfunction underlying obesity and type 2 diabetes more comprehensively than single-target therapies.
Current research focuses on several key areas: (1) optimizing the balance between GLP-1R and GCGR activation to maximize therapeutic benefits while minimizing side effects, (2) characterizing long-term safety and efficacy profiles in diverse patient populations, and (3) understanding the physiological advantages of dual receptor targeting compared to existing single-agonist therapies. The compound is being investigated primarily for obesity treatment, with potential applications in type 2 diabetes management, representing a significant advancement in peptide-based metabolic therapeutics.
Dosing Protocol
| Level | Dose | |
|---|---|---|
Beginner | 2 mg/wk | |
Intermediate | 3-5 mg/wk | |
Advanced | 6-8 mg/wk | |
Maximum | 10 mg/wk |
Select a dosing level and click Calculate to plan your protocol.
Vials Required
5
48.0 mg needed ÷ 10 per vial
Total Investment
$575
$115.00 per vial
Per Dose
0.40 mL
40 units on U-100 syringe
Doses per Vial
2
10 ÷ 4.00 mg/dose
* Calculations based on standard reconstitution protocols. Consult research guidelines for specific applications.
Compliance & Disclaimer
This product is intended for laboratory research purposes only. Not for human consumption. All products are sold with the understanding that the purchaser will comply with all applicable local, state, and federal laws regarding the purchase and use of research chemicals. Certificate of Analysis available upon request.
Survodutide
$115.00